Found 376 clinical trials
-
Phase 2 trial
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia
To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.
- 0 views
- 25 Jan, 2021
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Oncology
-
Currently Recruiting
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
interleukin-2 works in treating patients with metastatic kidney cancer.
- 17 views
- 07 Nov, 2020
- 2 locations
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
with advanced renal cancer.
- 0 views
- 25 Jan, 2021
- 26 locations
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Ketogenic Diet for Patients Receiving First Line Treatment for Metastatic Renal Cell Carcinoma
The purpose of this study is to evaluate the tolerance of one year of ketogenic diet associated with vitamin supplementation in patients treated for a metastatic renal cell carcinoma.
- 0 views
- 26 Jan, 2021
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients
active to warrant further investigation in randomized phase II or III studies. Metastatic renal cell cancer (mRCC) patients with PD-1 expressing immune cells are more likely to have larger more
- 0 views
- 26 Jan, 2021
- 3 locations
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Bevacizumab in Advanced Hepatocellular Carcinoma
liver cancer. Bevacizumab is an angiogenesis inhibitor already successfully used in patients with colorectal and renal cancers.
- 14 views
- 07 Nov, 2020
- 1 location
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC
Combination treatment of Durvalumab with chemoradiotherapy is ongoing for head/neck cancer, renal cell carcinoma, melanoma, and non-small cell lung cancer (NCT02318771) and pancreatic cancer
- 0 views
- 23 Jan, 2021
- 1 location
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Oncology
-
Currently Recruiting
Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma
molecule multi-kinase inhibitor of VEGFR, PDGFR and RAF with demonstrated activity in the treatment of renal cell cancer (9). Preclinical studies suggest that the combination of Sorafenib with
- 13 views
- 07 Nov, 2020
- 1 location
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Oncology
-
Currently Recruiting
Molecular Determinants for Therapy Response on Renal Cell Carcinoma
Aim of the scientific analysis is to find biological factors (biomarkers) allowing a prediction of disease progression and a better choice of therapy. After diagnosis the kidney and the tumor will be removed by standard surgery followed by drug therapy. Within surgery remaining tumor tissue will be used for the …
- 28 views
- 08 Nov, 2020
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
A Phase 1 Study of HLX20 a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors
This is an open-label, dose escalation, first-in-human study of HLX20, an anti-PD-L1 monoclonal antibody, in patients with metastatic or recurrent solid tumors who have failed standard therapy.
- 47 views
- 22 Jan, 2021
- 5 locations